


Anti-MRSA agent 5

Cat. No.:	HY-149013
CAS No.:	2490154-44-2
Molecular Formula:	C ₂₅ H ₂₂ N ₄ O ₄
Molecular Weight:	442.47
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	<p>Anti-MRSA agent 5 (B14) is a potent MRSA agent with MIC₅₀ values of 0.38 µg/mL and has low hERG activity with an IC₅₀ values of >40 µM. Anti-MRSA agent 5 (B14) also has low cytotoxicity to mammal cells and unlikely to acquire bacterial resistance^[1].</p>								
IC₅₀ & Target	MIC: 0.38 µg/mL (MRSA); IC ₅₀ : >40 Mm (hERG)								
In Vitro	<p>Anti-MRSA agent 5 (B14) is highly selective toxic in bacterial cells. Anti-MRSA agent has marginal inhibitory activities with an IC₅₀ values of exceeding 40 µM. Anti-MRSA agent 5 (B14) has strong antibacterial activity for all five clinical isolates of MRSA (NRS-1, NRS-70, NRS-100, NRS-108, NRS-271) with MIC values between < 0.17 and 0.69 µg/mL. Anti-MRSA agent 5 (B14) inhibits all three clinical isolates of fluoroquinolone-resistant MRSA (19-25, 19-26, 19-27) and exhibits good potency against VISA^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549, MDA-MB-231, PC-3, ABAE.</td> </tr> <tr> <td>Concentration:</td> <td>0–400 µM</td> </tr> <tr> <td>Incubation Time:</td> <td>48h</td> </tr> <tr> <td>Result:</td> <td>Showed marginal inhibitory activities with anIC₅₀ exceeding 40 µM and displayed highly selective toxicity toward bacterial cells.</td> </tr> </table>	Cell Line:	A549, MDA-MB-231, PC-3, ABAE.	Concentration:	0–400 µM	Incubation Time:	48h	Result:	Showed marginal inhibitory activities with anIC ₅₀ exceeding 40 µM and displayed highly selective toxicity toward bacterial cells.
Cell Line:	A549, MDA-MB-231, PC-3, ABAE.								
Concentration:	0–400 µM								
Incubation Time:	48h								
Result:	Showed marginal inhibitory activities with anIC ₅₀ exceeding 40 µM and displayed highly selective toxicity toward bacterial cells.								

REFERENCES

[1]. Runzhe Songa, et al, Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity, Bioorg Chem. 2020 Oct;103:104176.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA